Glaxosmithkline(Gsk) Bangladesh Ltd operates within the Medicinals and botanicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Glaxosmithkline(Gsk) Bangladesh Ltd with three other pharmaceutical manufacturers in Asia: High Tech Pharm Company., Limited of KOREA (SOUTH) (2019 sales of 63.07 billion Korean Won [US$53.61 million] of which 100% was Medicine), Mekophar Chemical Pharma JSC of VIETNAM (1.22 trillion Vietnamese Dong [US$52.46 million] ), and Panion & Bf Biotech Inc. which is based in TAIWAN (1.57 billion Taiwanese Dollars [US$53.77 million] of which 77% was Taiwan).

Sales Analysis. During the year ended December of 2019, sales at Glaxosmithkline(Gsk) Bangladesh Ltd were 4.47 billion Bangladeshi Taka (US$52.80 million). This is a decrease of 7.1% versus 2018, when the company's sales were 4.82 billion Bangladeshi Taka. Contributing to the drop in overall sales was the 11.1% decline in Powder, from 4.54 billion Bangladeshi Taka to 4.04 billion Bangladeshi Taka. . However, these declines were partially offset by the increase in sales of Oral (up 59.3% to 433.12 million Bangladeshi Taka) .